Navigation Links
Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting
Date:2/27/2012

the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.  Our actual results may differ materially from those indicated in the forward-looking statements.  Therefore, you should not rely on any of these forward-looking statements.  Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others:  (i) the statements regarding the therapeutic potential of NKTR-181 are based on preclinical data and data from the completed Phase 1 clinical studies and future clinical studies may not confirm one or more of these potential therapeutic benefits; (ii) although we have conducted various experiments using laboratory and home-based chemistry techniques that have so far been unable to convert NKTR-181 into a rapid-acting, more abusable opioid, there is a risk that an alternative chemistry technique or process may be discovered in the future that would enable the conversion of NKTR-181 into a more abusable opioid; (iii) NKTR-181 is in early stage clinical development and could fail at any time due to numerous unpredictable and significant risks related to safety, efficacy and other important findings that can negatively impact clinical development; (iv) the U.S. Food and Drug Administration and other regulatory agencies could impose significant risk mitigation requirements that hamper the commercial potential of NKTR-181, even if this drug candidate receives regulatory approval; (v) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platform to potential new drug candidates such as NKTR-181 is therefore very uncertain and unpredictable and could unexpectedly fail at any time; (vi) patents may not issue from our patent applications for NKTR-181, patents
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2011 on Wednesday, February 29, 2012, After Close of U.S.-Based Financial Markets
2. Positive Data for Nektars New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
3. Nektar Therapeutics Reports Third Quarter 2011 Financial Results
4. Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City
6. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
7. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
8. Nektar to Announce Financial Results for the Second Quarter of 2011 on Thursday, August 4, 2011, After Close of U.S.-Based Financial Markets
9. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
10. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
11. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... YORK , Aug. 20, 2014 ... is available in its catalogue: Global ... http://www.reportlinker.com/p01375204/Global-Coatings-for-Medical-Devices-Industry.html This report ... Devices in US$ Million by the following Product ... Nanotechnology Coatings. The report provides separate comprehensive analytics ...
(Date:8/20/2014)... and PHOENIX , ... established to bring cutting-edge next-generation sequencing and proteomic ... patients, today announced a collaboration with TESARO, Inc.  ... characterize patient tissue samples from clinical trials to ... resistant to TESARO,s TSR-011.  This may lead to more ...
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today announced ... platform during a special event at the company,s office ... on September 5, 2014. The event, which will start ... ApolloDx website, www.apollodx.com .    "We ... said Jared Bauer , Co-Founder and Managing Partner ...
Breaking Medicine Technology:Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2
... Inc. (Nasdaq: ENZN) announced today that four,posters containing ... Meeting of the American Association for Cancer Research,(AACR) ... 2007 in Los Angeles, CA., Details of the ... EZN-2208, a novel polyethyleneglycol-SN38,conjugate, has potent antitumor activity ...
... 13, 2007 - Point Therapeutics, Inc.,(NASDAQ: POTP) today ... 2007 Annual Meeting of the American,Association for Cancer ... 14-18, 2007. The AACR poster presentations report,on preclinical ... details for the AACR presentations are as,follows: , ...
Cached Medicine Technology:Enzon to Present Preclinical Data From PEG-SN38 and PEGylation,Technology Studies at AACR Meeting 2
(Date:8/21/2014)... (PRWEB) August 21, 2014 The rising numbers ... in Boynton Beach, FL. For many years, countless lives have ... difference in the community a new helpline was established to ... in Florida who are seeking to overcome their youth ... Teens Boynton Beach helpline at (561) 257-4053, parents and their ...
(Date:8/21/2014)... 21, 2014 CQIIP, Continuous Quality ... for Disease Control and Prevention and the Department ... compliance with the immunization standards and are administered ... General Recommendations on Immunizations. , ACC chose to ... procedures in place to protect patients, improve efficiency, ...
(Date:8/21/2014)... 2014 Recently nominated as the Women’s Radio ... journey to be the man he is today. Growing up, ... a positive look on women, respecting them as professionals and individuals. ... and thanks to a man who he had the pleasure of ... , KC Armstrong’s name will ring a bell to most of ...
(Date:8/21/2014)... 2014 Today, Fecbek.com, a leading wedding ... designs of wedding dresses. And all these elegant, gorgeous ... by excellent designers. , A wedding dress or wedding ... a wedding ceremony. Color, style and ceremonial importance of ... of the wedding participants. In order to satisfy every ...
(Date:8/20/2014)... 2014 On September 7th, 2014 Peoria will ... connects people living with MS with people who care. This ... are 85% of the way to their goal. This years ... at 11:30 and the walk starts at 1:00 pm. ... answer question about chiropractic care and how it helps symptoms ...
Breaking Medicine News(10 mins):Health News:Troubled Teens in Boynton Beach, FL Turn to Helpline for Valuable Assistance 2Health News:ACC Health Raises the Bar Again by Completing the CQIIP Certification Program 2Health News:WRNW1's KC Armstrong Expresses Thanks and Appreciation to Howard Stern 2Health News:Elegant Wedding Dresses Are for Sale at Fecbek.com 2Health News:Dr. Kelch of AlignLife North Peoria Supports Peoria Annual Walk MS 2
... INDIANAPOLIS, Sept. 14 In conjunction with today,s announcement ... to patients, Eli Lilly and Company (NYSE: ... Center of Excellence and its five business units: oncology, ... These leaders will provide improved line of sight to ...
... in dementia care is not so much related to equipment ... communication problems and misunderstandings. This is shown in a new ... Sweden. Dementia not only affects the memory and other ... to walk. ,The symptoms of dementia are very individual ...
... , AHIP to leverage MedAssurant,s datasets and ... affordability of healthcare. , , WASHINGTON, ... Inc., announced today that MedAssurant, through its healthcare data analytics ... quality and effectiveness of treatments. , , ...
... boosting the odds, experts say, , MONDAY, Sept. 14 (HealthDay ... the odds that a child will develop asthma or allergies, ... spent more than 1,000 hours swimming in chlorinated pools, either ... of having asthma than did teens who primarily swam in ...
... , , NCCN is ... forum to discuss the regulatory and operational aspects of research ... improvements can be made. Scheduled for October 26 - 27 ... and panel discussions on topics that challenge the conduct of ...
... Schizophrenia is a major public health problem. Affecting almost ... economic and social toll in addition to the distress, ... disease. Elements of the disease are present from birth, ... becomes fully expressed in early adulthood with long-lasting implications ...
Cached Medicine News:Health News:Lilly Names New Business Leaders 2Health News:Lilly Names New Business Leaders 3Health News:Lilly Names New Business Leaders 4Health News:Lilly Names New Business Leaders 5Health News:Lilly Names New Business Leaders 6Health News:Lilly Names New Business Leaders 7Health News:Lilly Names New Business Leaders 8Health News:Communication problems in dementia care cause physical strain 2Health News:MedAssurant to Support AHIP's Research Capabilities 2Health News:Chlorine in Pools Raises Kids' Asthma, Allergy Risk 2Health News:Chlorine in Pools Raises Kids' Asthma, Allergy Risk 3Health News:NCCN Holds Oncology Research Best Practices Conference 2Health News:NCCN Holds Oncology Research Best Practices Conference 3Health News:The future of schizophrenia 2Health News:The future of schizophrenia 3Health News:The future of schizophrenia 4Health News:The future of schizophrenia 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: